Endo Pharmaceuticals Announces Resignation of Chief Financial Officer

* Reuters is not responsible for the content in this press release.

Tue Sep 2, 2008 4:31pm EDT 

  CHADDS FORD, PA, Sep 02 (MARKET WIRE) -- 
Endo Pharmaceuticals (NASDAQ: ENDP) announced today that executive vice
president and chief financial officer, Charles A. Rowland, Jr., has
resigned effective immediately, to pursue other interests.

    "The Board and I wish to express our gratitude to Charlie for his
contributions and service and wish him well in his future endeavors," said
David Holveck, president and chief executive officer.

    Endo Pharmaceuticals has engaged an executive search firm to assist in the
search for a new chief financial officer.

    About Endo

    Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the
research, development, sale and marketing of branded and generic
prescription pharmaceuticals used primarily to treat and manage pain. More
information, including this and past press releases of Endo
Pharmaceuticals is available at www.endo.com.

    

CONTACT:
Blaine Davis
(610) 459-7158

Copyright 2008, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.